Adherence to Secondary Prevention Guidelines for Cardiovascular Risk

The present observational study aims to determine the degree of adherence to the recommendations of clinical guidelines regarding the prevention of cardiovascular complications in patients hospitalized due to a cardiovascular event.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atherosclerosis Acute Coronary Syndrome Arterial Occlusive Diseases Arteriosclerosis Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Heart Diseases Ischemic Heart Disease Ischemic Stroke Myocardial Ischemia Nervous System Diseases Peripheral Arterial Disease Peripheral Vascular Diseases Stroke Stroke, Ischemic Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Consorci Sanitari Alt Penedes i Garraf-Hospital Sant Camil

Sant Pere de Ribes, Barcelona, 08810, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Admitted to the cardiology, neurology, or general surgery departments
With any of the following admission diagnoses:

Non-ST-segment elevation acute coronary syndrome (NSTEACS) ST-segment elevation acute coronary syndrome (STEACS) Stable angina Unstable angina Non-ST-segment elevation myocardial infarction (NSTEMI) ST-segment elevation myocardial infarction (STEMI) Atherothrombotic ischemic stroke Lacunar stroke Peripheral artery disease Chronic ischemia of lower limbs Vascular ulcer due to arterial cause

Exclusion criteria

Patients for whom lipid-lowering treatment is ruled out due to limited life expectancy
Patients likely to die during hospitalization
Patients who died during hospitalization

Treatment and study plan

cardiovascular event

Other

In this single group observational trial the exposure of interest is a cardiovascular event.

Primary outcomes

patients admitted for a cardiovascular event who are prescribed lipid-lowering treatment at discharge

Time frame: Up to 3 months

Proportion of patients admitted for a cardiovascular event, warranting the initiation of secondary prevention with lipid-lowering agents, who are prescribed lipid-lowering treatment at discharge, adequate to reduce LDL by 50% or to below 55 mg/dL

Sponsors and collaborators

Lead sponsor

Consorci Sanitari de l'Alt Penedès i Garraf

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Jun 10, 2024
Registry last updated: Dec 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting